{
    "nctId": "NCT01640847",
    "briefTitle": "MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases",
    "officialTitle": "Phase II Trial of Phillips MRI-Guided High Intensity Focused Ultrasound (Sonalleve) and Lyso-thermosensitive Liposomal Doxorubicin (ThermoDox) for Palliation of Painful Bone Metastases",
    "overallStatus": "WITHDRAWN",
    "conditions": "Painful Bone Metastases, Breast Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Adenocarcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Rate of complete pain response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological confirmation of breast carcinoma, non-small cell lung cancer, small cell lung cancer, or adenocarcinoma of the prostate\n* Bone metastases index lesion in the ribs, clavicle, scapula, upper extremities, pelvis, or posterior aspects of the lumbar vertebra L3-L5 or sacral S1-S5.\n* Patients will have failed at least one prior attempt or will not be eligible for external beam radiation therapy (EBRT)\n\nExclusion Criteria:\n\n* Greater than 450 mg/m2 of prior free doxorubicin and/or non-heat activated liposomal doxorubicin\n* LVEF \\< 50%\n* Significant Cardiac History\n* Brain Metastases\n* Contraindication for MR imaging (as incompatible implanted metallic device, weight \\>250 lbs etc) or known intolerance or allergy to MRI contrast agents.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}